MedTrace Logo

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT07612137 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 282

Last updated 2026-05-28

No results posted yet for this study

Summary

To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

Conditions

Interventions

DRUG

IBI3005

Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)

DRUG

Sintilimab

Anti-PD-1 Monoclonal Antibody

DRUG

Bevacizumab biosimilar

Recombinant humanized anti-VEGF monoclonal antibody

DRUG

Limertinib

Third-generation EGFR-TKI

DRUG

Osimertinib

Third-generation EGFR-TKI

DRUG

Carboplatin

Second-generation platinum-based chemotherapy drugs

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07612137 on ClinicalTrials.gov